Please provide your email address to receive an email when new articles are posted on . Asundexian did not prevent stroke or systemic embolism vs. apixaban in patients with atrial fibrillation despite ...

New study includes patients aged ≥65 years with atrial fibrillation (AF) at high risk for ischemic stroke or systemic embolism who are deemed ineligible for oral anticoagulant (OAC) treatment due to ...

Catheter-directed thrombolysis (CDT) is associated with a lower risk for death and major bleeding complications than systemic thrombolysis for patients with intermediate- or high-risk pulmonary ...

Hamilton, ON - Atrial tachyarrhythmias in the absence of clinical atrial fibrillation occur frequently among patients with pacemakers and are associated with a significant increase in the risk for ...

PHILADELPHIA, PA—In patients with subclinical atrial fibrillation (AF) detected with an implantable device, apixaban (Eliquis; Bristol Myers Squibb) lowers the risk of stroke or systemic embolism ...

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot ...

Credit: Shutterstock. Asundexian is an investigational oral Factor XIa inhibitor. The Food and Drug Administration (FDA) has granted Fast Track designation to asundexian for the prevention of stroke ...

Please provide your email address to receive an email when new articles are posted on . Two studies found that mass screening for atrial fibrillation in older adults does not reduce stroke. In one ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

For patients with intermediate- to high-risk pulmonary embolism, catheter-directed thrombolysis (CDT) is associated with a lower risk for death and major bleeding than systemic thrombolysis and with a ...